Replies to post #214684 on Biotech Values

[DewDiligence]

...Eliquis up nearly 40 percent q3 2016 to q3 2017 is huge.

Eliquis has become the monster drug I originally thought it would be—before I thought I my original prediction was totally wrong during the early (slow) sales ramp. Lesson learned on not reaching a negative conclusion too soon for a drug with a very strong clinical dossier.

[DewDiligence]

BMY—Some bad writing from Bloomberg:

https://twitter.com/DewDiligence/status/924356573367029760